Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Date:6/1/2009

long-term tolerability of XERECEPT(R). Of the 113 patients enrolled, a total of 32 patients have completed one year or more of treatment in the study. Dexamethasone dosing of all patients on study was reduced progressively over time. Patients from the placebo cohort in the blinded studies entered this study with approximately double the mean dexamethasone dosing of patients from the prior active treatment cohort. The patient dosing of dexamethasone was reduced sharply once on XERECEPT(R), such that the difference between the two was no longer significant at 4 weeks. More than 50 percent of patients completing six months on study were able to achieve a virtual or complete elimination of corticosteroid treatment, and to sustain this for extended periods of time. The NTI-0501 study also showed that XERECEPT(R) therapy was well tolerated over extended periods up to two years or more.

"We are delighted to see the results from the three Phase III studies, the analysis of the brain scans from these studies, and the intriguing preclinical data regarding XERECEPT(R)," said Stephen Evans-Freke, co-Managing General Partner of Celtic Pharma. "We are especially interested in the data from the blinded and open-label studies indicating that XERECEPT(R) may offer significant clinical benefit for metastatic patients, given the very poor options available now for this substantial patient population. We look forward to reviewing these results with FDA and their European and Japanese counterparts before determining the forward path for this promising drug."

NTI-0302

NTI-0302, a Phase III randomized, double-blind study comparing XERECEPT(R) to dexamethasone for the control of acute symptoms associated with peritumoral edema, was discontinued due to slow enrollment. The study results from the 37 patients who enrolled show that XERECEPT(R) was as effective as 4mg/day of dexamethasone in the treatment of patients presenting with an a
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
5. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... Conference on Tuesday, June 9, 2015. Jeffrey Simmons ... will participate in a fireside chat at 2:20 p.m., ... webcast will be available on the "Webcasts & Presentations" ... A replay of the fireside chat will be available ...
(Date:5/29/2015)... SAN DIEGO and BOSTON ... a leader in instrument development, custom automation, and contract ... developer of the Nanopatch™ needle-free drug delivery technology, have ... for development of the Nanopatch Jet Coating Instrument ... drug delivery research and product development.  The award was ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3
... Thomson CompuMark , the global leader in trademark ... Reuters, today announced the launch of Global Pharmaceutical ... intelligence in a single online report. Avoiding ... to prescription errors, is a critically important public health ...
... Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will provide ... call on Friday, February 3, 2012, covering results for ... after the regular close of trading the preceding day. ... will be available online at www.spanamerica.com under ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3
(Date:5/29/2015)... Designed with the versatile athlete in mind, ... all new, exclusive line of supplementation called The 24/7 ... and greatest, high impact, result driven ingredients that have ... 24/7 Series can be used by anyone from bodybuilders ... fitness enthusiasts. There are no stimulant based ingredients that ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by the American Society ... May 14-19th. This global event sets a gold standard ... dedicating itself exclusively to cosmetic medicine. Dr. Paul Vitenas ... to attend this year’s meeting. , Among the classes and ... the honor of sitting at the presenter’s table during a ...
(Date:5/29/2015)... 2015 The report “Axillary ... comprehensive information on the therapeutic development for ... by identifying new targets and MOAs to ... on H1 2015 pipeline review of Axillary ... 13 figures, spread across 47 pages is ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... 2015 DISC, a method of behavioral ... behavior, is used by companies to improve hiring practices, ... once considered an out-of-the-box practice, has now become an ... from the Society for Human Resource Management found that ... DISC to be an essential part of the hiring ...
Breaking Medicine News(10 mins):Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:PeopleKeys to Air a Follow-up to Their Popular DISC Trainer’s Toolbox Webinar, Featuring All-New Content and Strategies 2
... ... of award-winning natural skin and hair care products for children, is reminding ... rays and potential toxins found in many sunscreens. TruKid has always ... dioxane, BPA and paraben free, offering excellent UVA/UVB protection SPF. We ...
... ... of Medical Genetics to meet virtual repository technology needs of the network, , ... Reston, VA (PRWEB) June ... the American College of Medical Genetics (ACMG) has selected the company to contribute web-based ...
... ... Ferro achieved explosive sales growth of 427 percent between 2007 - 2009 to qualify for ... described as a “win/win/win for all involved.” , ... Marlton, NJ (PRWEB) June 15, 2010 -- Amid all the ...
... ... must be eliminated to stop the terrible human suffering and environmental toll exacted through ... difference. , ... June 15, 2010 -- Adrian Desbarats, owner of an organic clothing company ...
... OAK BROOK, Ill. A new study suggests that computed ... of having pulmonary embolism (PE), based on the results of ... exposure and costs associated with CT angiography. The results of ... issue of the journal Radiology . ...
... could prevent 100,000 deaths worldwide each year, study suggests ... drug commonly used to prevent excess bleeding in surgeries ... after trauma, a new study suggests. , The drug, ... world and easily administered, experts said. It works by ...
Cached Medicine News:Health News:TruKid, the Award-Winning Line of Natural Products for Children, Wants to Help Keep your Kids Safe in the Sandbox this Summer 2Health News:TruKid, the Award-Winning Line of Natural Products for Children, Wants to Help Keep your Kids Safe in the Sandbox this Summer 3Health News:Technology Innovation Advances Newborn Screen Translational Research Network 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 3Health News:Free For All Honored for Explosive Growth, 2007 – 2009 2Health News:Free For All Honored for Explosive Growth, 2007 – 2009 3Health News:Organic Clothing – Is Your Clothing Delivering Death in Small Doses? 2Health News:Organic Clothing – Is Your Clothing Delivering Death in Small Doses? 3Health News:CT angiography may be unnecessary in patients with suspected pulmonary embolism 2Health News:Drug That Stops Bleeding Could Save Lives 2Health News:Drug That Stops Bleeding Could Save Lives 3